We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical (ISRG) Q2 Earnings: What's in Store?
Read MoreHide Full Article
Intuitive Surgical Inc (ISRG - Free Report) is set to report second-quarter 2016 results on Jul 19. Last quarter, the company reported earnings of $3.67 per share, which exceeded the Zacks Consensus Estimate by 21 cents.
We note that on an average, Intuitive Surgical posted a positive earnings surprise of 18.24% over the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
We believe that the growing adoption of the Da Vinci system among physicians for general surgery (hernia repair, colorectal) procedures is a key catalyst because it is increasing procedural volumes, especially outside the U.S.
Intuitive Surgical continues to focus on developing new products that enhance the capabilities of the da-Vinci system. The newly launched intra-operative Table Motion has already received strong customer feedback on its utility, particularly in general surgery.
Apart from the growing adoption of existing products and expanding portfolio, suspension of the medical device tax is likely to boost gross margin at least in the near term.
However, unfavorable currency fluctuations, increasing regulatory headwinds and low capital investment in hospitals are expected to be major dampeners.
Earnings Whispers
Our proven model does not conclusively show that Intuitive Surgical is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Intuitive Surgical currently has an Earnings ESP of +2.14%. This is because the Most Accurate estimate stands at $4.30 while the Zacks Consensus Estimate is $4.21.
Zacks Rank: Intuitive Surgical carries a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
CytRx Corporation with an Earnings ESP of +15.00% and a Zacks Rank #1.
Innoviva Inc. (INVA - Free Report) with an Earnings ESP of +25.00% and a Zacks Rank #1.
WellCare Health Plans Inc. with an Earnings ESP of +0.73% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intuitive Surgical (ISRG) Q2 Earnings: What's in Store?
Intuitive Surgical Inc (ISRG - Free Report) is set to report second-quarter 2016 results on Jul 19. Last quarter, the company reported earnings of $3.67 per share, which exceeded the Zacks Consensus Estimate by 21 cents.
We note that on an average, Intuitive Surgical posted a positive earnings surprise of 18.24% over the last four quarters.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
We believe that the growing adoption of the Da Vinci system among physicians for general surgery (hernia repair, colorectal) procedures is a key catalyst because it is increasing procedural volumes, especially outside the U.S.
Intuitive Surgical continues to focus on developing new products that enhance the capabilities of the da-Vinci system. The newly launched intra-operative Table Motion has already received strong customer feedback on its utility, particularly in general surgery.
INTUITIVE SURG Price and EPS Surprise
INTUITIVE SURG Price and EPS Surprise | INTUITIVE SURG Quote
Apart from the growing adoption of existing products and expanding portfolio, suspension of the medical device tax is likely to boost gross margin at least in the near term.
However, unfavorable currency fluctuations, increasing regulatory headwinds and low capital investment in hospitals are expected to be major dampeners.
Earnings Whispers
Our proven model does not conclusively show that Intuitive Surgical is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Intuitive Surgical currently has an Earnings ESP of +2.14%. This is because the Most Accurate estimate stands at $4.30 while the Zacks Consensus Estimate is $4.21.
Zacks Rank: Intuitive Surgical carries a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
CytRx Corporation with an Earnings ESP of +15.00% and a Zacks Rank #1.
Innoviva Inc. (INVA - Free Report) with an Earnings ESP of +25.00% and a Zacks Rank #1.
WellCare Health Plans Inc. with an Earnings ESP of +0.73% and a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>